What is Bafna Pharma share price and what are the returns for Bafna Pharma share?

Bafna Pharma share price is Rs 165.45 as on 12 Jun, 2026, 03:40 PM IST. Bafna Pharma share price is down by 5.00% based on previous share price of Rs 193.97.

What's the market capitalization of Bafna Pharma?

Bafna Pharma share has a market capitalization of Rs 391.39 Cr. Within Pharmaceuticals sector, it's market cap rank is 99.

What is Bafna Pharma's 52 week high / low?

Bafna Pharma share price saw a 52 week high of Rs 213.36 and 52 week low of Rs 72.01.

Bafna Pharmaceuticals Share Price

165.45-8.71 (-5.00%)

Closed
As On: 12 Jun, 2026, 03:40 PM IST
As On: 12 Jun, 2026, 03:40 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

STOCK SCORE

Unlock Scores

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	179.90
High	179.90
Low	165.45
Prev Close	174.15
Volume	67,584
VWAP(₹)	166.48

Share Price	Value
Today/Current/Last	165.45166.25
Previous Day	174.15174.95

Bafna Pharma Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Bafna Pharma Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

Income (P&L)

	Mar 2020	Dec 2019	Sep 2019	Jun 2019	Sep 2018
Total Income	12.46	10.96	12.16	7.15	8.80
Total Income Growth (%)	13.73	-9.86	70.00	-18.77	-26.90
Total Expenses	10.25	33.42	12.66	10.73	9.41
Total Expenses Growth (%)	-69.32	163.95	17.97	14.10	-36.31
EBIT	2.21	-22.47	-0.51	-3.58	-0.60
EBIT Growth (%)	-	-	-	-	-
Profit after Tax (PAT)	0.32	-22.33	-0.59	-2.13	-1.28
PAT Growth (%)	-	-	-	-	-
EBIT Margin (%)	17.71	-205.01	-4.17	-50.10	-6.86
Net Profit Margin (%)	2.55	-203.77	-4.86	-29.75	-14.50
Basic EPS (₹)	0.20	-94.39	-0.25	-0.90	-0.80

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	39.51	36.65	35.22	40.09	33.38
Total Income Growth (%)	7.80	4.06	-12.14	20.10	-19.27
Total Expenses	36.81	32.66	30.93	37.95	31.79
Total Expenses Growth (%)	12.70	5.61	-18.51	19.37	-16.56
EBIT	2.70	3.99	4.29	2.13	1.58
EBIT Growth (%)	-32.33	-7.10	101.31	34.75	-51.14
Profit after Tax (PAT)	1.84	3.12	3.39	1.31	0.95
PAT Growth (%)	-41.22	-7.79	158.50	38.33	-63.79
EBIT Margin (%)	6.83	10.89	12.19	5.32	4.74
Net Profit Margin (%)	4.65	8.53	9.62	3.27	2.84
Basic EPS (₹)	0.78	1.32	1.43	0.55	0.40

	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Total Revenue	42.73	44.01	78.50	66.10	87.30
Total Revenue Growth (%)	-2.92	-43.93	18.76	-24.28	-39.24
Total Expenses	44.61	62.31	93.22	86.46	102.62
Total Expenses Growth (%)	-28.40	-33.16	7.81	-15.74	-23.86
Profit after Tax (PAT)	-24.73	-18.87	-16.74	-19.09	-14.03
PAT Growth (%)	-	-	-	-	-327.07
Operating Profit Margin (%)	-4.20	-37.28	-16.47	-13.68	-2.76
Net Profit Margin (%)	-58.22	-43.52	-35.48	-29.38	-16.44
Basic EPS (₹)	-15.52	-11.48	-7.15	-10.43	-8.80

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	148.60	155.99	118.62	87.24	71.97
Total Revenue Growth (%)	-4.74	31.50	35.97	21.23	68.43
Total Expenses	142.30	148.64	107.01	79.93	66.14
Total Expenses Growth (%)	-4.26	38.91	33.87	20.86	48.28
Profit after Tax (PAT)	4.15	7.35	11.34	5.15	5.83
PAT Growth (%)	-43.49	-35.19	120.11	-11.59	-
Operating Profit Margin (%)	6.19	6.32	11.83	9.51	9.22
Net Profit Margin (%)	2.84	4.81	9.82	6.05	8.18
Basic EPS (₹)	1.76	3.11	4.86	2.17	2.46

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 2.43% of its operating revenues towards interest expenses and 14.55% towards employee cost in the year ending Mar 31, 2026. (Source: Standalone Financials)

View Details

Balance Sheet

Annual	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Total Assets	71.31	119.47	138.36	178.31	192.71
Total Assets Growth (%)	-40.31	-13.65	-22.40	-7.47	-3.57
Total Liabilities	20.12	100.62	101.16	136.20	134.95
Total Liabilities Growth (%)	-80.01	-0.53	-25.72	0.92	6.17
Total Equity	51.20	18.85	37.20	42.11	57.75
Total Equity Growth (%)	171.56	-49.33	-11.66	-27.08	-20.58
Current Ratio (x)	2.11	0.68	0.81	0.95	1.29
Total Debt to Equity (x)	-0.71	2.43	1.23	1.93	1.39
Contingent Liabilities	-	-	0.46	0.29	1.64

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	153.08	147.68	129.58	90.24	86.47
Total Assets Growth (%)	3.66	13.97	43.59	4.36	21.69
Total Liabilities	68.27	66.84	56.13	27.36	29.69
Total Liabilities Growth (%)	2.14	19.08	105.15	-7.85	47.56
Total Equity	84.81	80.84	73.45	62.88	56.77
Total Equity Growth (%)	4.91	10.06	16.81	10.76	11.42
Current Ratio (x)	1.66	1.75	1.88	3.14	2.04
Total Debt to Equity (x)	0.33	0.30	0.31	0.13	0.04
Contingent Liabilities	10.74	10.75	10.48	2.42	-

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Net Cash flow from Operating Activities	-34.31	-1.79	-7.05	-0.95	0.91
Net Cash used in Investing Activities	32.77	14.93	37.97	-5.42	-0.36
Net Cash flow from Financing Activities	7.30	-13.38	-30.63	6.31	-0.61
Net Cash Flow	5.77	-0.24	0.29	-0.06	-0.06
Closing Cash & Cash Equivalent	8.48	2.71	2.95	2.66	2.71
Closing Cash & Cash Equivalent Growth (%)	212.57	-8.06	11.04	-2.06	-2.04
Total Debt/ CFO (x)	-0.09	-25.87	-6.60	-86.98	88.35

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	22.14	9.48	4.95	8.03	-13.61
Net Cash used in Investing Activities	-21.16	-15.05	-7.49	-5.44	-5.35
Net Cash flow from Financing Activities	1.06	-0.85	10.18	-4.22	12.28
Net Cash Flow	2.04	-6.41	7.64	-1.63	-6.68
Closing Cash & Cash Equivalent	3.43	1.40	7.81	0.17	1.80
Closing Cash & Cash Equivalent Growth (%)	145.90	-82.13	4,414.45	-90.41	-78.73
Total Debt/ CFO (x)	1.27	2.57	4.63	0.98	-0.18

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 22.4 cr for investing activities which is an YoY increase of 5.85%. (Source: Standalone Financials)

View Details

Ratios

Annual	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Return on Equity (%)	0.00	-99.01	-44.12	-44.73	-24.28
Return on Capital Employed (%)	-3.29	-33.22	-9.90	-9.17	-2.41
Return on Assets (%)	-34.67	-15.79	-12.09	-10.70	-7.27
Interest Coverage Ratio (x)	-18.72	-7.60	-1.12	-0.77	-0.18
Asset Turnover Ratio (x)	59.55	36.29	34.09	36.43	44.27
Price to Earnings (x)	-0.08	-1.37	-3.96	-2.89	-3.98
Price to Book (x)	-0.49	1.36	1.75	1.29	0.97
EV/EBITDA (x)	-2.22	-5.45	-28.71	-28.76	53.52
EBITDA Margin (%)	3.48	-29.26	-8.05	-7.18	2.92

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	4.89	9.08	15.43	8.19	10.26
Return on Capital Employed (%)	8.91	10.29	16.42	10.96	10.56
Return on Assets (%)	2.71	4.97	8.74	5.70	6.73
Interest Coverage Ratio (x)	5.10	6.39	9.32	17.13	8.85
Asset Turnover Ratio (x)	0.97	1.10	1.05	0.96	82.36
Price to Earnings (x)	42.74	24.69	17.27	58.48	55.87
Price to Book (x)	2.09	2.24	2.66	4.78	5.72
EV/EBITDA (x)	14.53	13.96	11.09	22.67	29.47
EBITDA Margin (%)	9.54	9.59	16.46	15.96	15.51

Found Financials useful?

5 Days	14 Days	28 Days
-	-	-

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Bafna Pharma	35.26	7.65	0.00	-3.29	-34.67	9.31	-4.20	-57.54	-15.52	2.11	-0.71	-0.09
Medico Remedies	27.06	4.70	17.37	26.22	8.54	13.57	9.62	6.35	1.58	1.66	0.25	3.21
Nectar Lifesc	-0.77	0.39	-50.29	-8.74	-47.11	-81.59	0.00	0.00	-13.40	9.59	0.00	0.00
Aarey Drugs	48.81	1.47	2.63	6.84	1.33	4.25	2.20	0.84	1.39	1.81	0.33	4.93
Natural Capsule	-7.00	0.69	-7.70	-5.82	-4.02	2.96	-9.06	-13.17	-23.84	1.03	0.52	10.47
Add More

Annual Ratios (%)

Choose from Peers

Alpa Labs
Krebs Biochem
Bal Pharma
Par Drugs & Chemical
Vaishali Pharma

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Bafna Pharma Stock Performance	-5.00	21.74	21.25	46.74	122.80	84.04	20.68
Medico Remedies Stock Performance	3.14	-1.32	4.27	-6.86	-22.91	-48.41	0.00
Nectar Lifesc Stock Performance	1.76	-9.10	-4.77	-8.16	-52.40	-31.01	-60.78
Aarey Drugs Stock Performance	2.30	-14.73	-11.70	-0.85	46.14	178.04	0.00
Natural Capsule Stock Performance	1.57	0.07	-2.93	-1.30	-21.57	0.00	0.00
Add More

Category	No. of Shares	Percentage
Promoters	1,77,42,251	75.00 %
Pledge	0	0.00 %
FII	22,09,803	9.34 %
Others	37,04,281	15.65 %

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	75.00	75.00	75.00	75.00
Pledge	0.00	0.00	0.00	0.00
FII	9.34	9.34	9.34	9.34
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	15.65	15.65	15.65	15.65

Mutual Funds Ownership

No Data Available

Corporate Actions

Recent
Board Meeting
Audited Results
May 21, 2026
Board Meeting
Quarterly Results
Feb 05, 2026
Board Meeting
Quarterly Results
Nov 06, 2025

Board Meetings

Announced on	Meeting on
May 21, 2026	May 29, 2026
Audited Results
Feb 05, 2026	Feb 11, 2026
Quarterly Results
Nov 06, 2025	Nov 11, 2025
Quarterly Results
Aug 07, 2025	Aug 12, 2025
Quarterly Results
May 19, 2025	May 26, 2025
Audited Results

Dividends
Announced on Ex-Date Dividend%
May 21, 2013 Sep 19, 2013 6%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available

Announced on	Ex-Date	Dividend%
May 21, 2013	Sep 19, 2013	6%

AGM/EGM Meetings

Announced on	Meeting on
Aug 21, 2025	Sep 19, 2025
-
Aug 14, 2024	Sep 25, 2024
A.G.M.
Aug 11, 2023	Sep 22, 2023
-
May 26, 2022	Jul 28, 2022
Book closure from Jul 22, 2022 to Jul 28, 2022
Jun 25, 2021	Aug 14, 2021
Book closure from Aug 7, 2021 to Aug 14, 2021

About Bafna Pharma

Bafna Pharmaceuticals Ltd., incorporated in the year 1995, is a Small Cap company (having a market cap of Rs 391.39 Crore) operating in Pharmaceuticals sector.

Bafna Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals and Other Operating Revenue for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Standalone Total Income of Rs 44.00 Crore, up 11.38 % from last quarter Total Income of Rs 39.51 Crore and up 9.77 % from last year same quarter Total Income of Rs 40.09 Crore. Company has reported net profit after tax of Rs 2.75 Crore in latest quarter.

The company’s top management includes Mr.Bafna Mahaveer Chand, Mrs.S Hemalatha, Mr.Vinayak Dinesh Dendukuri, Mrs.Akila C Raju, Mr.Upendar Mekala Reddy, Mr.Navin Kumar, Ms.R Chitra, Mr.Melagiri Sridhar, Mr.A Mohanachandran. Company has Brahmayya & Co. as its auditors. As on 31-03-2026, the company has a total of 2.37 Crore shares outstanding.

Bafna Pharma Share Price Today is Rs. 165.45. On previous day, the Bafna Pharma Share Price (NSE) closed at Rs. 165.86, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 75.0% of the stake in Bafna Pharma shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Bafna Pharma stocks was 9.34% as compared to 9.34% in Dec 2025 with decrease of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with null of 0.0%. Out of the total DII holdings in Bafna Pharma shares 0.0% was held by mutual funds. The rest including public held is 0.0%. Bafna Pharma stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Bafna Pharma Dividend: Ever since 1995, Bafna Pharma dividends has been paid out around 1 times. As on 12 Jun, 2026, 03:40 PM IST, The overall dividend yield for Bafna Pharma stands at 0.0%. The last dividend paid was on September 19, 2013 (Rs. 0.6). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 4.69.

Bafna Pharma Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 44.0 Cr. of sales and 11.38% of quarterly net profit, there have been multiple ups and downs in the Bafna Pharma stock prices in the past few weeks. For example, Bafna Pharma stock price on 4th of June 2026 was around Rs. 160.31. Bafna Pharma share price now stands at an average of Rs. 165.45. Judging by last week's performance, stock is in up trend.

Bafna Pharma has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Bafna Pharma share.

Historical Prices and Performance:
Bafna Pharma, incorporated in 1995 is a Small Cap company (with a market cap of Rs. 411.98) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Bafna Pharma stock was 11.54%, 4.89%, 9.08%, 15.43% and 8.19% respectively.
The Bafna Pharma share gave a 3 year return of 41.7% as compared to Nifty 50 which gave a return of 25.67%.
Bafna Pharma announced 6.0% final dividend on September 19, 2013.

Key Metrics:
PE Ratio of Bafna Pharma is 37.12
Prices/Sales Ratio of Bafna Pharma is 0.05
Price/Book Ratio of Bafna Pharma is 8.05

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Bafna Pharma, major competitors and peers include Medico Remedies, Nectar Lifesc, Aarey Drugs and Natural Capsule. As of Dec 2025, the dividend yield of Bafna Pharma stands at 0.0% while Medico Remedies, Nectar Lifesc, Aarey Drugs and Natural Capsule stand at 0.0%, 0.0%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 37.12 and 8.05 respectively.

Leadership of Bafna Pharma :
A Mohanachandran is Co. Secretary & Compl. Officer
Melagiri Sridhar is Chief Financial Officer
Bafna Mahaveer Chand is Chief Executive Officer
S Hemalatha is Whole Time Director
Vinayak Dinesh Dendukuri is Whole Time Director
Upendar Mekala Reddy is Non Exe.Non Ind.Director
Akila C Raju is Non Exe.Non Ind.Director
R Chitra is Ind. Non-Executive Director
Navin Kumar is Ind. Non-Executive Director

Industry

Pharma - Indian

Key Indices Listed On

-

Address

Bafna Towers,New�No.�68,�Old�No. 299,Chennai (Madras), Tamil Nadu - 600001

Contact

info@bafnapharma.com

http://www.bafnapharma.com

PE Ratio(x)	35.26
EPS - TTM(₹)	4.69
MCap(₹ Cr.)	391.39
MCap Rank	99
PB Ratio(x)	7.66
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	213.36
52W Low(₹)	72.01
MCap/Sales	0.05
Beta(1 Month)	-0.15
BV/Share(₹)	21.64

PE Ratio(x)	35.43
EPS - TTM(₹)	4.69
MCap(₹ Cr.)	393.29
MCap Rank	106
PB Ratio(x)	8.04
Div Yield(%)	-
Face Value(₹)	10.00
52W High(₹)	216.25
52W Low(₹)	72.25
MCap/Sales	0.05
Beta(1 Month)	0.42
BV/Share(₹)	21.64

1 Day	-5.0%
1 Month	24.4%
3 Months	59.42%
1 Year	126.27%
3 Years	39.92%
5 Years	15.9%

1 Day	-4.97%
1 Month	19.05%
3 Months	61.96%
1 Year	123.42%
3 Years	39.35%
5 Years	15.73%

R1	-	Pivot -	S1	-
R2	-		S2	-
R3	-		S3	-

Bafna Pharmaceuticals Share Price

Key Metrics

Bafna Pharma share price insights

Bafna Pharma Share Price Returns

Bafna Pharma Share Recommendations

News & Analysis

Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Financials

Technicals

Peer Comparison

Shareholding Pattern

Mutual Funds Ownership

Bafna Pharma Top Searches

Corporate Actions

About Bafna Pharma

Executive Leadership

Auditors

FAQs about Bafna Pharma share

Top Gainers

Top Losers

Equity Quick Links

More from Markets

Trending in Markets

Browse Companies

Popular Categories

Hot on Web

In Case you missed it

Top Searched Companies

Latest News